Cargando…
Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland
Short stature resulting from SGA is an obligatory indication for treatment with rhGH. The aim of the study was to assess the response to rhGH treatment in patients treated in the years 2016–2020 in six clinical centers in Poland. During the analysis, auxological data were collected, and anthropometr...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181578/ https://www.ncbi.nlm.nih.gov/pubmed/35683483 http://dx.doi.org/10.3390/jcm11113096 |
_version_ | 1784723810853847040 |
---|---|
author | Glińska, Marta Walczak, Mieczysław Wikiera, Beata Pyrżak, Beata Majcher, Anna Paluchowska, Monika Gawlik, Aneta Antosz, Aleksandra Kusz, Marcin Bossowski, Artur Stożek, Karolina Wędrychowicz, Anna Starzyk, Jerzy Petriczko, Elżbieta |
author_facet | Glińska, Marta Walczak, Mieczysław Wikiera, Beata Pyrżak, Beata Majcher, Anna Paluchowska, Monika Gawlik, Aneta Antosz, Aleksandra Kusz, Marcin Bossowski, Artur Stożek, Karolina Wędrychowicz, Anna Starzyk, Jerzy Petriczko, Elżbieta |
author_sort | Glińska, Marta |
collection | PubMed |
description | Short stature resulting from SGA is an obligatory indication for treatment with rhGH. The aim of the study was to assess the response to rhGH treatment in patients treated in the years 2016–2020 in six clinical centers in Poland. During the analysis, auxological data were collected, and anthropometrical parameters (Ht, SDS Ht, HV and ΔHV) were reassessed. Subgroups of patients with dysmorphic features (DYSM), fetal alcohol syndrome (FAS) and Silver-Russel syndrome (SRS) were selected. The study group consisted of 235 children (137 boys). The medium initial age was 9.08 years, and 190 patients were in the prepubertal stage. The poor response to treatment was defined as ΔHt SDS < 0.3 and/or ΔHV < 3 cm/year. Seventeen per cent of all patients after the first year and 44% after the second year met the ΔHt SDS < 0.3 criterion, and 56% during the first and 73% during the second year met the ΔHV < 3 cm/year criterion. Our data suggest that patients with SRS may show the best response to treatment, which was sustained throughout the follow-up period. The best response in all subgroups was observed during the first 12 months of therapy. Although the proportion of patients meeting the poor response criteria was high, only a few patients exceeded the 97th percentile for IGF-1 concentration during the first year of treatment. This might suggest that increasing the dose of rhGH in the second treatment year in order to sustain accelerated HV would be safe in these patients. |
format | Online Article Text |
id | pubmed-9181578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91815782022-06-10 Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland Glińska, Marta Walczak, Mieczysław Wikiera, Beata Pyrżak, Beata Majcher, Anna Paluchowska, Monika Gawlik, Aneta Antosz, Aleksandra Kusz, Marcin Bossowski, Artur Stożek, Karolina Wędrychowicz, Anna Starzyk, Jerzy Petriczko, Elżbieta J Clin Med Article Short stature resulting from SGA is an obligatory indication for treatment with rhGH. The aim of the study was to assess the response to rhGH treatment in patients treated in the years 2016–2020 in six clinical centers in Poland. During the analysis, auxological data were collected, and anthropometrical parameters (Ht, SDS Ht, HV and ΔHV) were reassessed. Subgroups of patients with dysmorphic features (DYSM), fetal alcohol syndrome (FAS) and Silver-Russel syndrome (SRS) were selected. The study group consisted of 235 children (137 boys). The medium initial age was 9.08 years, and 190 patients were in the prepubertal stage. The poor response to treatment was defined as ΔHt SDS < 0.3 and/or ΔHV < 3 cm/year. Seventeen per cent of all patients after the first year and 44% after the second year met the ΔHt SDS < 0.3 criterion, and 56% during the first and 73% during the second year met the ΔHV < 3 cm/year criterion. Our data suggest that patients with SRS may show the best response to treatment, which was sustained throughout the follow-up period. The best response in all subgroups was observed during the first 12 months of therapy. Although the proportion of patients meeting the poor response criteria was high, only a few patients exceeded the 97th percentile for IGF-1 concentration during the first year of treatment. This might suggest that increasing the dose of rhGH in the second treatment year in order to sustain accelerated HV would be safe in these patients. MDPI 2022-05-30 /pmc/articles/PMC9181578/ /pubmed/35683483 http://dx.doi.org/10.3390/jcm11113096 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Glińska, Marta Walczak, Mieczysław Wikiera, Beata Pyrżak, Beata Majcher, Anna Paluchowska, Monika Gawlik, Aneta Antosz, Aleksandra Kusz, Marcin Bossowski, Artur Stożek, Karolina Wędrychowicz, Anna Starzyk, Jerzy Petriczko, Elżbieta Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland |
title | Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland |
title_full | Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland |
title_fullStr | Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland |
title_full_unstemmed | Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland |
title_short | Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland |
title_sort | response to treatment with recombinant human growth hormone (rhgh) of short stature children born too small for gestational age (sga) in selected centres in poland |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181578/ https://www.ncbi.nlm.nih.gov/pubmed/35683483 http://dx.doi.org/10.3390/jcm11113096 |
work_keys_str_mv | AT glinskamarta responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT walczakmieczysław responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT wikierabeata responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT pyrzakbeata responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT majcheranna responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT paluchowskamonika responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT gawlikaneta responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT antoszaleksandra responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT kuszmarcin responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT bossowskiartur responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT stozekkarolina responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT wedrychowiczanna responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT starzykjerzy responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland AT petriczkoelzbieta responsetotreatmentwithrecombinanthumangrowthhormonerhghofshortstaturechildrenborntoosmallforgestationalagesgainselectedcentresinpoland |